A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer
PHASE3CompletedINTERVENTIONAL
Enrollment
276
Participants
Timeline
Start Date
July 31, 2014
Primary Completion Date
November 30, 2015
Study Completion Date
November 30, 2015
Conditions
Symptomatic Colorectal CancerAdvanced Colorectal CancerColorectal Cancer With Cachexia
Interventions
BIOLOGICAL
Xilonix
BIOLOGICAL
Placebo
Trial Locations (1)
Unknown
XBiotech Investigative Site, Warsaw
All Listed Sponsors
lead
Janssen Research & Development, LLC
INDUSTRY
NCT02138422 - A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer | Biotech Hunter | Biotech Hunter